November Momentum: Presenting at ALS/MND Symposium, Joining NVIDIA Inception, and Advancing R&D

Canurta Therapeutics to Showcase Research at the International Symposium on ALS/MND

Canurta Therapeutics will present our latest research at the 35th International Symposium on ALS/MND on December 7, 2024, in Montreal. Hosted by the Motor Neuron Disease Association, this event is the largest global conference dedicated to ALS/MND research.

Our poster presentation, "IVV-40: Therapeutic Potential of Cannabis-Derived Formulations in Mitigating Motor Neuron Disease," outlining the progress of our CNR-400s botanical formulations. These findings showcase their potential to enhance motor function and restore neuronal health in models of ALS and frontotemporal dementia.

Explore our abstract under Theme 04, page 22 and learn more about how CNR-400s may redefine therapeutic approaches to ALS.

Learn More

CEO Akeem Gardner at the CB1, CB2 & Cannabinoid Drug Development Summit

Canurta’s CEO, Akeem Gardner, was honored to speak at the 7th Annual CB1, CB2 & Cannabinoid Drug Development Summit from November 18-20, 2024, in Boston. Akeem’s presentation, “Evolving Cannabinoid Drug Development: Next-Generation Multi-Target Therapeutics,” explored innovative therapeutic strategies for neurodegenerative conditions like ALS.

He detailed Canurta's advancements in combining cannabinoids, terpenes, and flavonoids to develop multi-target therapies and leveraging cutting-edge technologies like AI for enhanced drug discovery.

Presenting at the Life Sciences Investor Forum

On November 14, 2024, Canurta Therapeutics participated in the Life Sciences Investor Forum, a virtual platform that brings together a global audience of investors and stakeholders. This platform provided an opportunity to connect with investors, discuss Canurta's innovative pipeline, and explore collaborative opportunities in biotechnology.

Learn More

Selected for the Canada-Chicago Mentoring Program (C2MP)

Canurta Therapeutics has been selected as one of five innovative companies to join the prestigious Canada-Chicago Mentoring Program (C2MP). Supported by the Trade Commissioner Service and MATTER, this program is designed to accelerate Canadian companies in the U.S. market.

Through tailored mentorship and expanded network access, this initiative will strengthen our business development efforts and enhance our position in the global life sciences industry.

Canurta Joins NVIDIA Inception Program

We are pleased to announce Canurta Therapeutics' acceptance into the NVIDIA Inception Program. This collaboration offers access to NVIDIA's advanced technical resources and expertise, enhancing our bioinformatics and R&D capabilities.

With NVIDIA’s support, we aim to further innovate in neuroinflammatory and neurodegenerative research, leveraging tools like machine learning to refine our therapeutic formulations.

Learn More

Canurta's November Milestones

Research and Development

Our research team is advancing cutting-edge standardization and analytical methods for its pharmaceutical products to ensure both safety and quality.

Bioinformatics

This month, the team made progress on molecular fingerprinting methods, enhancing batch-to-batch consistency and quality control. Our RNASeq analysis from the TargetALS Postmortem Tissue Core has also identified potential ALS biomarkers, an essential step in our efforts to combat neurodegeneration.